<span item_type="fundamental" item_id="bb05b103bff60a9d43ba07f666fbb36d" counter_id="ST/US/CAH" env="prod"></span><span item_type="announcement" item_id="577206743870279169" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 64.01 B, beating the estimate of USD 59.27 B.</p><p>EPS: As of FY2026 Q1, the actual value is USD 1.88, beating the estimate of USD 1.7882.</p><p>EBIT: As of FY2026 Q1, the actual value is USD 678 M.</p><p></p><h3>Revenue</h3><ul><li>Total revenue increased by 22% to $64 billion in Q1 FY26 from $52.3 billion in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li></ul><h3>Operating Earnings</h3><ul><li>GAAP operating earnings increased by 18% to $668 million in Q1 FY26 from $568 million in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li><li>Non-GAAP operating earnings increased by 37% to $857 million in Q1 FY26 from $625 million in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li></ul><h3>Net Earnings</h3><ul><li>Net earnings attributable to Cardinal Health, Inc. increased by 8% to $450 million in Q1 FY26 from $416 million in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li><li>Non-GAAP net earnings attributable to Cardinal Health, Inc. increased by 33% to $611 million in Q1 FY26 from $460 million in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li></ul><h3>Effective Tax Rate</h3><ul><li>GAAP effective tax rate was 24.1% in Q1 FY26 compared to 23.0% in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li><li>Non-GAAP effective tax rate was 21.9% in Q1 FY26 compared to 23.0% in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li></ul><h3>Diluted EPS</h3><ul><li>GAAP diluted EPS increased by 11% to $1.88 in Q1 FY26 from $1.70 in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li><li>Non-GAAP diluted EPS increased by 36% to $2.55 in Q1 FY26 from $1.88 in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li></ul><h3>Segment Results</h3><h4>Pharmaceutical and Specialty Solutions</h4><ul><li>Revenue increased by 23% to $59.2 billion in Q1 FY26 from $48.0 billion in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li><li>Segment profit increased by 26% to $667 million in Q1 FY26 from $530 million in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li></ul><h4>Global Medical Products and Distribution</h4><ul><li>Revenue increased by 2% to $3.2 billion in Q1 FY26 from $3.1 billion in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li><li>Segment profit increased to $46 million in Q1 FY26 from $8 million in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li></ul><h4>Other</h4><ul><li>Revenue increased by 38% to $1.6 billion in Q1 FY26 from $1.2 billion in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li><li>Segment profit increased by 60% to $166 million in Q1 FY26 from $104 million in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash provided by operating activities was $973 million in Q1 FY26 compared to - $1,647 million in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li><li>Non-GAAP adjusted free cash flow was $1,269 million in Q1 FY26 compared to - $1,361 million in Q1 FY25.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Cardinal Health raised its fiscal year 2026 non-GAAP EPS guidance to $9.65 to $9.85 and non-GAAP adjusted free cash flow outlook to $3.0 to $3.5 billion.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li><li>The company anticipates completing the acquisition of Solaris Health in early November.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li><li>Updated guidance reflects increased expectations at the segment level, with Pharmaceutical and Specialty Solutions segment profit growth raised to 16% to 19% and Other segment profit growth raised to 29% to 31%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/721371/000072137125000128/a26q1_x093025xex991xnewsre.htm"></span></li></ul>

Cardinal Health | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 64.01 B